Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 2Dermatologic 2

Conditions

Hodgkin Disease 27Lymphoma 22Hematologic Diseases 20Lymphoma, Large-Cell, Anaplastic 16Lymphoma, Non-Hodgkin 11Recurrence 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 4Lymphoma, T-Cell, Cutaneous 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Melanoma 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphomatoid Papulosis 1

Interventions

Rituximab 3Brentuximab Vedotin 2venetoclax 1veltuzumab 1pirtobrutinib 1ontuxizumab 1iratumumab 1exatecan 1durvalumab 1Zidovudine 1Vincristine 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Prednisone 1Prednisolone 1Oxaliplatin 1Mitoxantrone 1Mannose-Binding Lectin 1Lenalidomide 1Gemcitabine 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bendamustine Hydrochloride 1Antibodies, Monoclonal 1Adrenal Cortex Hormones 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Dendritic Cell Sarcoma, Interdigitating × Brentuximab Vedotin × Clear all
NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00051597 2011-10-12

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Seagen Inc.

Phase 1/2 Completed
70 enrolled
DermatologicLymphoidSarcoma

Hodgkin Disease, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡